Used as a potent and selective inhibitor of cyclin-dependent kinases (CDKs), particularly CDK4 and CDK6, this compound plays a key role in regulating the cell cycle. It is primarily investigated for its anticancer properties, especially in the treatment of solid tumors and hematological malignancies. By blocking CDK4/6 activity, it helps prevent uncontrolled cell proliferation, a hallmark of cancer. It has shown promising results in preclinical studies for breast cancer, lung cancer, and other cancers dependent on CDK4/6 pathways. Its vinyl and piperazine-containing structure enhances cellular permeability and target binding, making it a valuable scaffold in developing targeted cancer therapies.